Akston Biosciences

Akston Biosciences Corporation is a privately held biotechnology company headquartered in Beverly, Massachusetts, founded in 2011 by the team from SmartCells, Inc. and led by CEO Todd Zion, Ph.D. Akston designs, develops and manufactures protein therapeutics built on its proprietary Ambifect Fc-fusion protein platform, with a pipeline focused on companion-animal (veterinary) medicine: PD-L1 monoclonal antibody oncology candidates (AKS-701d, AKS-619d), a long-acting GLP-1 for feline weight management (AKS-562c), an IL-31 targeting therapy for canine pruritus (AKS-699), and NGF-targeting candidates for osteoarthritis pain. Its veterinary insulin program was sold to Dechra in 2024, and human programs continue through the Vakston and Diamune Therapeutics subsidiaries. The company announced a manufacturing expansion in Shreveport, Louisiana. Akston is a therapeutics developer and manufacturer, not a software vendor: it publishes a corporate marketing site and no public API, SDK, developer portal or machine-readable specification.

Akston Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Pharmaceuticals, and Animal Health.

Akston Biosciences’ developer surface includes engineering blog and 9 more developer resources.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyLife SciencesPharmaceuticalsAnimal HealthVeterinary MedicineProtein TherapeuticsBiomanufacturing

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/akston-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 7

The organization behind the API

Website

About

Blog

BlogRSS

Careers

Partners

LinkedIn

Scroll for all 7

Other 1

Properties that don't map to a standard resource type

Team

Team

Source (apis.yml)

aid: akston-biosciences
name: Akston Biosciences
description: 'Akston Biosciences Corporation is a privately held biotechnology company headquartered in Beverly, Massachusetts,
  founded in 2011 by the team from SmartCells, Inc. and led by CEO Todd Zion, Ph.D. Akston designs, develops and manufactures
  protein therapeutics built on its proprietary Ambifect Fc-fusion protein platform, with a pipeline focused on companion-animal
  (veterinary) medicine: PD-L1 monoclonal antibody oncology candidates (AKS-701d, AKS-619d), a long-acting GLP-1 for feline
  weight management (AKS-562c), an IL-31 targeting therapy for canine pruritus (AKS-699), and NGF-targeting candidates for
  osteoarthritis pain. Its veterinary insulin program was sold to Dechra in 2024, and human programs continue through the
  Vakston and Diamune Therapeutics subsidiaries. The company announced a manufacturing expansion in Shreveport, Louisiana.
  Akston is a therapeutics developer and manufacturer, not a software vendor: it publishes a corporate marketing site and
  no public API, SDK, developer portal or machine-readable specification.'
url: https://raw.githubusercontent.com/api-evangelist/akston-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
image: https://www.akstonbio.com/wp-content/themes/ssw-akston/assets/images/header/akston-logo.svg
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Life Sciences
- Pharmaceuticals
- Animal Health
- Veterinary Medicine
- Protein Therapeutics
- Biomanufacturing
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.akstonbio.com/
- type: About
  url: https://www.akstonbio.com/about/
- type: Blog
  url: https://www.akstonbio.com/news/
- type: BlogRSS
  url: https://www.akstonbio.com/feed/
- type: Contact
  url: https://www.akstonbio.com/contact/
- type: Careers
  url: https://www.akstonbio.com/careers/
- type: Team
  url: https://www.akstonbio.com/team/
- type: Partners
  url: https://www.akstonbio.com/partners/
- type: LinkedIn
  url: https://www.linkedin.com/company/akston-biosciences-corporation/
- type: DomainSecurity
  url: security/akston-biosciences-domain-security.yml
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Akston Biosciences is a veterinary protein-therapeutics developer and manufacturer whose entire web presence is
    a nine-page WordPress marketing site (about/process/pipeline/news/careers/contact) with no developer section; api., developer.,
    docs. and portal.akstonbio.com are all NXDOMAIN and every spec and .well-known probe returned 404.
  evidence:
  - url: https://www.akstonbio.com/openapi.json
    status: 404
  - url: https://www.akstonbio.com/llms.txt
    status: 404
  - url: https://www.akstonbio.com/.well-known/agent-card.json
    status: 404
  - url: https://www.akstonbio.com/.well-known/security.txt
    status: 404
  - url: https://www.akstonbio.com/sitemap.xml
    status: 200
  checked: '2026-08-06'